Focused on treatments for rare neurological diseases, the company is a clinical‑stage biotechnology developer advancing therapies that use autologous red blood cells to deliver drugs. Its lead program, EryDex, is being studied as a potential treatment for ataxia‑telangiectasia, a rare inherited diso...
No congressional trades have been disclosed for Quince Therapeutics Inc (QNCX) yet. All data is sourced from STOCK Act periodic transaction reports filed with Congress.
No congressional trades found for this stock.